Paris, 09/27/2023
Delbert Pharma, a major player in the safeguarding and relocation of essential medicines, is proud to announce that it has officially been awarded Mission-driven company status in September 2023.
This recognition, the fruit of intense collaborative work and a deep commitment to patients, is in line with the company’s core values: guaranteeing access to treatments critical to public health. Since its creation in 2002, Delbert Pharma has distinguished itself by its primary mission: to prevent the disappearance of essential medicines deemed insufficiently profitable by the pharmaceutical industry. This ambition, rooted in the company’s ethical values, aims to combat the loss of opportunity for patients by ensuring the availability of drugs of major therapeutic interest.
A mission for the common good
The Mission-driven company status, introduced by the 2019 PACTE law, enables companies to formalize their commitment to social and environmental objectives, while continuing their economic activity. At Delbert Pharma, this approach is reflected in precise statutory objectives, integrated into the company’s articles of association, aimed at:
– Maintaining and developing medicines whose absence would harm patients and the balance of healthcare systems.
– Relocating production to Europe to preserve exceptional know-how while reducing the ecological footprint.
– Offering a working ecosystem that promotes the well-being of employees and partners.
A collective commitment to public health.
Obtaining this status marks a turning point in the history of Delbert Pharma, uniting all our teams and partners around our mission. “We have always placed patients’ interests at the heart of our actions, by guaranteeing access to treatments without alternatives. This status is official recognition of our efforts, and commits us to continuing along this path,” explains Thierry Hoffmann, co-founder of Delbert Pharma.
Next steps
With an ambitious roadmap, Delbert Pharma is committed to publishing an annual mission report, overseen by a mission committee made up of internal and external stakeholders. The report will track progress in the areas of public health, quality of working life and environmental responsibility.
Delbert Pharma is one of only two mission-driven pharmaceutical companies in France, illustrating its determination to combine economic performance with social utility.
” This approach, supported by our raison d’être and our statutory objectives, involves all our teams, federates them, and makes the company shine beyond our walls” mentions Eric Fidelin, Executive General Manager of Delbert Pharma. For further information, please contact: Delbert Pharma
Telephone: 01 46 99 68 20
E-mail: contact@delbert.fr
Website: www.delbertpharma.com